# RELATIVITY-047 (NCT03470922)

> A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03470922
- Phase: PHASE2, PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bristol-Myers Squibb
- Conditions: Melanoma
- Interventions: Relatlimab; Nivolumab
- Enrollment: 714
- Primary outcome: Progression Free Survival (PFS)

## Commentary we found

- Podcasts: 36
- YouTube: 26
- X threads: 15

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=relativity-047-nct03470922

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03470922", "email": "<work email>"}; the inbox owner confirms by the emailed link.